TripAdvisor (TRIP) PT Raised to $63 at Credit Suisse Following 3Q

TripAdvisor (TRIP) PT Raised to $45 at Mizuho Securities

Mizuho Securities analyst James Lee raised the price target on TripAdvisor (NASDAQ: TRIP) to $45.00 (from $42.00) while maintaining a Neutral rating following the company's 3Q earnings report. Sales and marketing expense came in at 44% of revenue vs. 55% in 3Q17. Performance marketing expenses are still... More

UBS Downgrades TripAdvisor (TRIP) to Sell

UBS analyst Eric Sheridan downgraded TripAdvisor (NASDAQ: TRIP) from Neutral to Sell with a price target of $50.00 (from $47.00).

For an analyst ratings summary and ratings history on TripAdvisor click here. For more ratings news on TripAdvisor click here.

Shares of TripAdvisor closed at $65.80 yesterday.

TripAdvisor (TRIP) PT Raised to $59 at Deutsche Bank

Deutsche Bank analyst Lloyd Walmsley raised the price target on TripAdvisor (NASDAQ: TRIP) to $59.00 (from $57.00) while maintaining a Hold rating.

TripAdvisor (TRIP) PT Raised to $78 at Barclays

Barclays analyst Deepak Mathivana raised the price target on TripAdvisor (NASDAQ: TRIP) to $78.00 (from $68.00) while maintaining a Overweight rating.

TripAdvisor (TRIP) PT Raised to $57 at Stifel

Stifel analyst Scott Devitt raised the price target on TripAdvisor (NASDAQ: TRIP) to $57.00 (from $48.00) while maintaining a Hold rating.

TripAdvisor (TRIP) PT Raised to $66 at RBC Capital

RBC Capital analyst Mark Mahaney raised the price target on TripAdvisor (NASDAQ: TRIP) to $66.00 (from $50.00) while maintaining a Sector Perform rating.

While Q3 Revenue missed EBITDA was "way, way above" thanks to material reductions in Hotel segment marketing spend.

TripAdvisor (TRIP) PT Raised to $47 at Guggenheim

Guggenheim analyst Jake Fuller raised the price target on TripAdvisor (NASDAQ: TRIP) to $47.00 (from $40.00) while maintaining a Sell rating.

Pre-Open Movers 11/08: (CVNA) (PTLA) (CYBR) Higher; (VYGR) (KRO) (ZAYO) Lower (more...)

Today's Pre-Open Movers

Voyager Therapeutics, Inc. (NASDAQ: VYGR) 20% LOWER; announced positive longer-term results from the open-label, dose-escalating Phase 1b trial of VY-AADC demonstrating sustained improvements in patients motor function. Patients in the two highest dose cohorts (Cohorts 3 and 2) experienced mean improvements in diary on-time without troublesome dyskinesia (good ON time) of 1.7 hours per day at 18 months and 2.7 hours per day at two years, respectively.

Kronos Worldwide, Inc. (NYSE: KRO) 18% LOWER; reported net... More

TripAdvisor (TRIP) PT Raised to $54 at Piper Jaffray

Piper Jaffray analyst Michael Olson raised the price target on TripAdvisor (NASDAQ: TRIP) to $54.00 (from $50.00) while maintaining a Neutral rating.

TripAdvisor (TRIP) Tops Q3 EPS by 24c

TripAdvisor (NASDAQ: TRIP) reported Q3 EPS of $0.72, $0.24 better than the analyst estimate of $0.48. Revenue for the quarter came in at $458 million versus the consensus estimate of $468.55 million.

For earnings history and earnings-related data on TripAdvisor (TRIP) click here.